Seminar Title: “Strategic Overview of Complex Excipients in US Pharmacopeia (USP)”
Friday, November 17, 2023 – 12:30 pm – 1:30 pm - PBB 131
https://uconn-cmr.webex.com/meet/xil11015
Research:
Otilia Koo is a recognized leader in the pharmaceutical sciences who has bridged small molecules, biologics, and cell therapies. Dr. Koo’s position in the pharmaceutical sciences is demonstrated by her role as an Executive Director in Global Product Development and Supply Program Management at Bristol Myers Squibb. While at BMS, she has been an integral part of developing and launching Evotaz® and Ximency™. She invented, obtained proof of concept in pivotal clinical studies, and scaled up these two products that were important for the treatment of HIV/AIDs and Hepatitis C. Dr. Koo also led the development of 20 or more BMS small molecules and biologics for oncology, immunology, and virology. She contributed to the successful approval and launch of two cell therapy products at BMS, where she is one of the rare pharmaceutical scientists who lead programs in the areas of small molecules, biologics, and cell therapies. Dr. Koo has served on the USP Council of Experts, which further demonstrates the community’s recognition of her scientific leadership.
For more information, contact: Deirdre McAvoy at deirdre.mcavoy@uconn.edu